Pharmacokinetic evaluation of losartan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 5, 2011, Pages 643-649

  Burnier, Michel ^a   Wuerzner, Grégoire ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

angiotensin II receptor; antagonists; clinical pharmacology; humans; hypertension

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; E 3179; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; UNCLASSIFIED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRESSLER SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; GENE FREQUENCY; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PRESCRIPTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LOSARTAN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955107269     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.570333     Document Type: Article

References (30)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52 (Pubitemid 37553153)
2. Mancia G, De BG, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751-62 (Pubitemid 47356612)
3. Chrysant SG, Chrysant GS, Chrysant C, Shiraz M. The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr Clin Pharmacol 2010;5:89-95
4. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12 (Pubitemid 32163892)
5. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 (Pubitemid 351522739)
6. Chiu AT, McCall DE, Price WA Jr, et al. In vitro pharmacology of DuP 753. Am J Hypertens 1991;4:282S-7S
7. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814 (Pubitemid 41126929)
8. Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89-98 (Pubitemid 34124042)
9. Li Z, Wang G, Wang LS, et al. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009;39:788-93
10. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25 (Pubitemid 27475226)
11. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-42
12. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13 (Pubitemid 23120227)
13. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21
14. Maillard MP, Wurzner G, Nussberger J, et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002;71:68-76 (Pubitemid 34124040)
15. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25 (Pubitemid 351822111)
16. Vauquelin G, Fierens F, Van L, I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl 2006;24:S23-30
17. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31-6 (Pubitemid 36056788)
18. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5 (Pubitemid 29140445)
19. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60 (Pubitemid 35247704)
20. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7 (Pubitemid 30240502)
21. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
22. Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
23. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8
24. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46 (Pubitemid 351793017)
25. Meier P, Maillard MP, Meier JR, et al. Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. J Hypertens, in press, 2011
26. Coltamai L, Maillard M, Simon A, et al. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens 2010;28:520-6
27. Mohanram A, Zhang Z, Shahinfar S, et al. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008;73:630-6 (Pubitemid 351264116)
28. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47 (Pubitemid 23254082)
29. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7
30. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9 (Pubitemid 38251080)